Junior Dissecting Board |
|||
M618 | Scientific Laboratory Supplies | EACH | EUR 196.8 |
Human IgG antibody Laboratories manufactures the cricket spikes junior reagents distributed by Genprice. The Cricket Spikes Junior reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike S. Other Cricket products are available in stock. Specificity: Cricket Category: Spikes Group: Junior
True north Cryobox 5mLBlue |
||
Scientific Laboratory Supplies | PK10 | EUR 153.6 |
True north Cryobox 15mLNatural |
||
Scientific Laboratory Supplies | PK10 | EUR 212.4 |
True north Cryobox 15mLBlue |
||
Scientific Laboratory Supplies | PK10 | EUR 212.4 |
True north Cryobox 50mLNatural |
||
Scientific Laboratory Supplies | PK10 | EUR 210 |
True north Cryobox 50mLBlue |
||
Scientific Laboratory Supplies | PK10 | EUR 210 |
True north Cryobox1.5/2mLNatural |
||
Scientific Laboratory Supplies | PK10 | EUR 162 |
True north Cryobox1.5/2.0mLGreen |
||
Scientific Laboratory Supplies | PK10 | EUR 162 |
Spike S1 (16-685), Fc Fusion, Avi-tag (SARS-CoV-2) |
|||
100719-1 | BPS Bioscience | 100 µg | EUR 320 |
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 expression system, MW=104 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
Spike S1 (16-685), Fc Fusion, Avi-tag (SARS-CoV-2) |
|||
100719-2 | BPS Bioscience | 1 mg | EUR 2720 |
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 expression system, MW=104 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag |
|||
E80021 | EpiGentek |
|
|
SARS-CoV-2 (COVID-19) Spike 156-157EF Antibody |
|||
9685-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: SARS-CoV-2 delta variant, a variant of concern (VOC), known as B.1.617.2, was detected in India in October of 2020. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 99% of the cases. This variant carries at least 13 mutations in spike protein across the sub lineages, including L452R, D614G, P681R and K417N, which can increase the affinity to the human ACE2 receptor. Enhanced transmission of the Delta variant was observed globally, which is at least 2.5 times more contagious as the other variants. The Delta variant affects the effectiveness of COVID19 vaccine and is resistant to neutralization to some extent. |
SARS-CoV-2 (COVID-19) Spike 156-157EF Antibody |
|||
9685-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: SARS-CoV-2 delta variant, a variant of concern (VOC), known as B.1.617.2, was detected in India in October of 2020. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 99% of the cases. This variant carries at least 13 mutations in spike protein across the sub lineages, including L452R, D614G, P681R and K417N, which can increase the affinity to the human ACE2 receptor. Enhanced transmission of the Delta variant was observed globally, which is at least 2.5 times more contagious as the other variants. The Delta variant affects the effectiveness of COVID19 vaccine and is resistant to neutralization to some extent. |
SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag |
|||
E80020 | EpiGentek |
|
|
SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag |
|||
E80022 | EpiGentek |
|
|
Spike S1 (B.1.351), Avi-His-Tag (SARS-CoV-2) |
|||
100992-1 | BPS Bioscience | 100 µg | EUR 320 |
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.351 originally identified in South Africa and contains mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The recombinant protein is ≥90% pure following affinity purification. |
Spike S1 (B.1.351), Avi-His-Tag (SARS-CoV-2) |
|||
100992-2 | BPS Bioscience | 1 mg | EUR 2850 |
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.351 originally identified in South Africa and contains mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The recombinant protein is ≥90% pure following affinity purification. |
Spike S1 (16-685), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2) |
|||
100731-1 | BPS Bioscience | 20 µg | EUR 310 |
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified and enzymatically biotinylated using the Avi-Tag™. |
Spike S1 (16-685), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2) |
|||
100731-2 | BPS Bioscience | 50 µg | EUR 455 |
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified and enzymatically biotinylated using the Avi-Tag™. |
SARS Spike |
|||
ant-157 | ProSpec Tany | 5µg | EUR 175 |
Description: Polyclonal Rabbit Anti SARS Spike Protein |
SARS Spike |
|||
ant-758 | ProSpec Tany | 5µg | EUR 175 |
Description: Mouse Anti SARS Spike |
Spike S1 (13-665), Fc fusion, Avi-tag, Biotin-Labeled (SARS-CoV-2) |
|||
100679-1 | BPS Bioscience | 20 µg | EUR 305 |
Description: Human Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 13-665, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=102 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
Spike S1 (13-665), Fc fusion, Avi-tag, Biotin-Labeled (SARS-CoV-2) |
|||
100679-2 | BPS Bioscience | 50 µg | EUR 450 |
Description: Human Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 13-665, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=102 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
Spike S1 (16-685), Fc Fusion, Avi-tag, Biotin-labeled (SARS-CoV-2) |
|||
100720-1 | BPS Bioscience | 25 µg | EUR 295 |
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=104 kDa. This protein runs at a higher molecular weight due to glycosylation. |
Spike S1 (16-685), Fc Fusion, Avi-tag, Biotin-labeled (SARS-CoV-2) |
|||
100720-2 | BPS Bioscience | 50 µg | EUR 435 |
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=104 kDa. This protein runs at a higher molecular weight due to glycosylation. |